Navigation Links
Amilpar - Relevant Fact - Public Offer Result
Date:1/29/2010

RIO DE JANEIRO, Jan. 29 /PRNewswire-FirstCall/ -- Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3.SA), the largest managed care organization in Brazil, in accordance with article 157, paragraph 4, of Law 6,404/76 (Brazilian Corporate Law) and CVM Instruction no. 358/02, informs its shareholders and the market that its subsidiary Amil Assistencia Medica Internacional Ltda. ("Applicant") acquired, in the Public Offer auction (Tag Along) for the acquisition of common shares issued by Medial Saude S.A. ("Auction"), made on January 28, 2010, in the Bm&fBOVESPA, 31,841,504 common shares issued by Medial Saude S.A., representing 45.7% of its total capital, for the price of R$ 17.50 per share (R$ 17.2066 plus the SELIC rate), totalling R$ 557,226,320.00. Considering the shares acquired in the offer, the Applicant now holds 97.6% of the total capital of Medial Saude S.A.

    To access the Relevant Fact, visit our website at www.amilpar.com.br/ir.

    IR Contact
    Erwin Kleuser
    Investor Relations Officer
    Phone: +55 (21) 3805-1155
    invest@amil.com.br
    www.amilpar.com.br/ir

SOURCE Amilpar

RELATED LINKS
http://www.amilpar.com.br/ir

'/>"/>

SOURCE Amilpar
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amilpar - Press Release
2. Amilpar - Distribution of Interest on Capital Stock
3. Amilpar - Relevant Fact
4. Amilpar - Press Release - Commercial Papers
5. Amilpar - Relevant Fact - Public Offer
6. Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09
7. Amilpar - Operating Revenues Grew 9% in the Second Quarter and 11% in the First Half of 2009
8. Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009
9. Amilpar - Revenues Increase by 26.5% and Adjusted Net Income Climbs 28.7% in 2008
10. Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock
11. Amilpar Revenues Grow 28% in the First 9 Months of 2008 and 4.5% Over Previous Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Boca Raton, FL (PRWEB) , ... January 21, 2017 , ... ... from Germany, announced it is bringing its product to the United States as part ... perfected over the last 25 years, Alcovit aims to reduce the productions of nasty ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body ... oils, announced the company had a successful visit to the 2017 ECRM Diet, Vitamin ... companies that work in the nutritional, sports and health industries a chance to meet ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based ... recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting from ... large range of supplements that keep the body functioning at its peak performance ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... James Gilbart , ... 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... recently in a supplement to European Oncology & ... article by James Gilbart and ...
(Date:1/19/2017)... PALO ALTO, Calif. , Jan. 19, 2017 /PRNewswire/ ... scientific research, is excited to announce that the ... Project: Cancer Biology  (RP:CB) have been published in ... science, this project represents the first practical evaluation ... that result in reproducible studies. Unlike other assessments ...
Breaking Medicine Technology: